Tagged with GEN

Switzerland With the pharmaceutical landscape growing increasingly complex, few mid-sized players manage to carve out a distinct, resilient path. Rivopharm, a Swiss-headquartered generics manufacturer, is doing just that, expanding its direct presence across Europe, targeting technically demanding niche products, and balancing growth with operational precision. In this interview, CEO Piero Poli…

Switzerland What if the key to treating chronic and age-related diseases has been hidden in plain sight, within the 98 percent of the human genome once written off as “junk”? HAYA Therapeutics is betting on it. In this interview, CEO and Scientific Co-Founder Samir Ounzain reveals how his obsession with the…

Hong Kong With global momentum building around CRISPR-based therapeutics, GenEditBio stands at the frontier of in vivo genome editing, developing next-generation delivery platforms designed for both precision and safety. In this conversation, Dr Zongli Zheng, Co-founder and Chair, shares how his scientific path from Boston to Hong Kong, shaped by pioneering work…

USA Regeneron has agreed to pay USD 256 million to acquire at-home DNA test maker 23andMe after the troubled firm declared bankruptcy. Through the buyout, Regeneron will acquire the data of 23andMe’s customers, obtaining the valuable genetic profiles of millions to potentially develop new and lucrative therapies. With ambiguous legal guidelines…

Switzerland Daniela Marino, CEO and co-founder of CUTISS, leads a pioneering Swiss “tech-bio” company developing personalised skin grafts through advanced tissue engineering. With roots in academic research and over EUR 90 million raised, CUTISS has brought its lead product into Phase III trials, targeting burns and reconstructive surgery. Their unique approach…

Global 2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the number of greenlit therapies. With seven new approvals and three expanded indications, the cell and gene therapies authorized by the…

Puerto Rico Glorimar Torres, with over 33 years in the pharmaceutical industry, has had a diverse career, starting as a sales representative in Puerto Rico and progressing through key roles at companies like Merck & Co. (MSD), Bristol Myers Squibb, Pfizer, and GlaxoSmithKline (GSK) before joining Amgen. At Amgen, she played a…

Hong Kong Few biotech companies emerge with both scientific depth and a clear sense of direction. Innorna, founded by Dr Linxian Li after years spent refining RNA delivery systems in academic settings, is one of them. What began as a technical platform matured through a pandemic-era proof of concept and now moves…

Saudi Arabia Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare payer in the country and, with medicines already consuming over 20 percent of national healthcare spending, is putting increasing emphasis…

Hong Kong At the Centre for Oncology and Immunology, a flagship of Hong Kong’s Health@InnoHK initiative, science converges across disciplines and continents. Under the leadership of Professor Tak Wah Mak, the Centre is advancing a new understanding of how immune responses are shaped, not only by tumours, but by the nervous system…

Hong Kong With Asia-Pacific poised to become a global force in cell and gene therapy, Xellera Therapeutics is positioning itself at the heart of this transformation. Led by CEO Camie Chan, the Hong Kong-based company is bridging critical infrastructure gaps by offering GMP-certified manufacturing, regulatory compliance aligned with global standards, and a…

Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…